Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: NVA237 50µg once daily
Drug: Tiotropium 18µg once daily
Drug: Flu/Sal
Drug: NVA237 placebo + Tiotropium placebo.

First Posted Date: 2012-01-20

Last Posted Date: 2015-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 773

Registration Number: NCT01513460

Locations: 🇳🇿
Novartis Investigative Site, Wellington, New Zealand

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

Phase 3

Terminated

Conditions: Relapsing Remitting Multiple Sclerosis (RRMS)

Interventions: Drug: Fingolimod
Drug: Placebo

First Posted Date: 2011-12-26

Last Posted Date: 2014-08-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 142

Registration Number: NCT01499667

Locations: 🇨🇭
Novartis Investigative Site, Basel, Switzerland

Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy

Phase 4

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Fingolimod (FTY720)

First Posted Date: 2011-12-26

Last Posted Date: 2019-01-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 347

Registration Number: NCT01498887

Locations: 🇪🇸
Novartis Investigative Site, Santa Cruz de Tenerife, Spain

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Fingolimod

First Posted Date: 2011-12-22

Last Posted Date: 2015-03-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 162

Registration Number: NCT01497262

Locations: 🇵🇪
Novartis Investigative Site, San Isidro, Lima, Peru

Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Vildagliptin
Drug: Placebo

First Posted Date: 2011-12-22

Last Posted Date: 2017-02-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 183

Registration Number: NCT01497522

Locations: 🇯🇵
Novartis Investigative Site, Kyoto, Japan

Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Inoperable Locally Advanced Breast Cancer
Metastatic Breast Cancer (MBC)

Interventions: Drug: BEZ235
Drug: Paclitaxel

First Posted Date: 2011-12-19

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT01495247

Locations: 🇪🇸
Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain

INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.

Phase 3

Completed

Conditions: Myelofibrosis

Interventions: Drug: INC424

First Posted Date: 2011-12-16

Last Posted Date: 2019-04-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2233

Registration Number: NCT01493414

Locations: 🇹🇳
Novartis Investigative Site, Tunis, Tunisia

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Phase 2

Completed

Conditions: Parkinsonian Disorders
Anti-Dyskinesia Agents
Parkinson Disease
Dyskinesias
Movement Disorders

Interventions: Drug: AFQ056

First Posted Date: 2011-12-14

Last Posted Date: 2020-12-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 129

Registration Number: NCT01491932

Locations: 🇨🇭
Novartis Investigative Site, Bern, Switzerland

Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma

Phase 2

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: RAD001

First Posted Date: 2011-12-14

Last Posted Date: 2016-06-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 134

Registration Number: NCT01491672

Locations: 🇷🇺
Novartis Investigative Site, Obninsk, Russia, Russian Federation
🇺🇸
Memorial Sloan Kettering Cancer Center, NY, New York, United States

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Phase 2

Completed

Conditions: Parkinson Disease
Parkinsonian Disorders
Anti-Dyskinesia Agents
Dyskinesias
Movement Disorders

Interventions: Drug: AFQ056
Drug: Placebo

First Posted Date: 2011-12-14

Last Posted Date: 2020-12-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 154

Registration Number: NCT01491529

Locations: 🇨🇭
Novartis Investigative Site, Lausanne, Switzerland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy